Quantum Health Signs Agreement to Acquire Embold Health
DUBLIN, Ohio & NASHVILLE, Tenn.--(BUSINESS WIRE)--Jun 4, 2025--
Quantum Health ('Quantum'), the creator of healthcare navigation, has signed a definitive agreement to acquire Embold Health ('Embold'), a leading physician-led healthcare technology company. The transaction is expected to close within the next 14 days, subject to customary closing conditions and regulatory approvals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604551686/en/
This strategic move deepens Quantum's investment in AI-powered personalization, significantly enhancing its Real-Time Intercept ® (RTI) and provider engagement capabilities to guide members to cost-effective, high-quality care while driving ROI for clients. Together, Quantum and Embold will offer an expanded portfolio of products to the market.
'By joining forces, we're not just adding technology — we're elevating the standard for healthcare navigation,' said Dayne Williams, CEO of Quantum. 'Our Healthcare Warriors ®, already known for their compassion and expertise, will be equipped with even more powerful tools to guide members to the best care. When you combine our high provider and member Net Promoter Scores ® (NPS) with Embold's AI, you get a complete, intelligent and human-centered navigation experience built to deliver ROI.'
The acquisition builds on a strong existing partnership between the two organizations. By pairing Embold's proven provider quality analytics and conversational AI capabilities with Quantum's 26-year legacy of navigation expertise and unparalleled provider relationships, the combined entity is well-positioned to redefine the way consumers engage with healthcare.
Embold will continue to operate as an independent entity, upholding its commitment to delivering exceptional service to its clients. With enhanced investment and resources from Quantum, Embold will accelerate the advancement of its product roadmap, further strengthening its ability to serve clients with innovative, data-driven solutions.
'This is about bringing together two companies with shared missions,' said Dr. Daniel Stein, CEO and Founder of Embold, who will now serve as President of Embold. 'Together, we remain focused on delivering the trusted insights our clients count on, with enhanced capabilities to help even more members access higher-quality care.'
Integrating with Embold's proprietary physician-level analytics and AI-powered provider recommendation engine, Quantum will deliver the most complete navigation experience in the industry — one that balances trust, quality and action. The combined company will serve more than 8 million members nationwide, increasing the scale and scope of its products and capabilities.
Raymond James & Associates, Inc. served as financial advisor, and Mayer Brown LLP served as legal counsel to Embold Health, while Kirkland & Ellis LLP served as legal counsel to Quantum.
About Quantum Health
Quantum Health is the industry-leading consumer healthcare navigation and care coordination company that delivers an unparalleled consumer experience to its members, as well as validated claims savings and high satisfaction rates for its self-insured employer and payer clients. Quantum Health's proprietary Real-Time Intercept® capability identifies opportunities for early intervention in a member's healthcare journey, resulting in better engagement, outcomes and cost efficiencies.
Founded in 1999 and based in Dublin, Ohio, Quantum Health has earned numerous awards and honors, including being named among the Fastest-Growing Private Companies by Inc. 5000, a Great Place to Work by FORTUNE Magazine and Entrepreneur Magazine, and one of FORTUNE'S Best Workplaces in Healthcare. The Women Presidents' Organization has also ranked Quantum Health as one of the 50 Fastest-Growing Women-Owned/Led Companies for over 15 years.
To learn more about the company, visit www.Quantum-Health.com, and connect with us on LinkedIn and X.
About Embold Health
Embold Health, a healthcare technology company, helps employers and health plans improve outcomes and lower costs by empowering members to make informed healthcare decisions. Evaluating 21 specialties and 68 sub-specialties, Embold's patented and peer-reviewed provider quality score methodology analyzes data from 230+ million individuals across the entire care journey at the individual physician performance level. Setting the standard for responsible AI in healthcare, Embold's conversational AI simplifies the care-seeking process. Paving the way for more efficient, personalized, and cost-effective care, Embold is transforming how care is sought out and delivered. To learn more, visit emboldhealth.com.
Disclaimer
This announcement contains forward-looking statements, which are subject to risks and uncertainties. These statements include, but are not limited to, expectations regarding the completion and timing of the proposed acquisition. Actual results may differ materially due to various factors, including the satisfaction of closing conditions and other unforeseen developments.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250604551686/en/
CONTACT: Media Contact
Alison Travis
Corporate Communications Manager
[email protected]
220-465-9386
KEYWORD: TENNESSEE OHIO UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: TECHNOLOGY HEALTH TECHNOLOGY PROFESSIONAL SERVICES SOFTWARE PRACTICE MANAGEMENT GENERAL HEALTH DATA ANALYTICS HEALTH DATA MANAGEMENT ARTIFICIAL INTELLIGENCE
SOURCE: Quantum Health
Copyright Business Wire 2025.
PUB: 06/04/2025 08:15 AM/DISC: 06/04/2025 08:15 AM
http://www.businesswire.com/news/home/20250604551686/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Wedbush Boosts IBM Target to $32
Wedbush kept an Outperform on IBM (NYSE:IBM) and lifted its price target to $325 from $300, betting on a new AI-fueled growth phase. Analysts led by Daniel Ives cited fresh field checks showing robust demand for IBM's software cloud and AI offerings. IBM features prominently on Wedbush's AI 30 list, reflecting conviction that it's underowned despite strong YTD performance. Warning! GuruFocus has detected 10 Warning Signs with ADI. The firm points to IBM's $6 billion+ GenAI book as a runway for sustained top-line expansion, with ongoing product launches aimed at capturing emerging use cases. A key catalyst is the continued shift toward hybrid cloud and containerized AIWedbush expects 75% of AI workloads to run in containers by 2027. On the ground, Ives' team sees momentum across WatsonX, AI agents, Red Hat, and OpenShift as enterprises lean on IBM to architect AI strategies. Looking further ahead, IBM's quantum roadmapincluding the upcoming Quantum Nighthawk chip and its Quantum Starling platformpositions it to tackle the multibillion-dollar quantum computing market. IBM's blend of legacy hybrid-cloud strength, accelerating GenAI adoption, and early quantum forays differentiates it from peers. As more enterprises seek productivity gains from AI, IBM's broad portfolio could unlock higher-margin software growth and defend its leadership in enterprise IT. Investors should monitor GenAI revenue cadence, container penetration rates, and early quantum milestones to validate whether IBM's renaissance accelerates toward that $325 target. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
16 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
a day ago
- Yahoo
Tensec raises $12M to boost growth
This story was originally published on Payments Dive. To receive daily news and insights, subscribe to our free daily Payments Dive newsletter. Tensec, the Palo Alto, California-based cross-border payments startup, has raised $12 million, the company announced Wednesday. Costanoa Ventures led the funding round, with seven other firms, including Quiet Capital, WillowTree Investments, Cambrian VC and Ignia Partners, also participating in the round, the release said The funding will support the company's efforts to facilitate cross-border payments, real-time payments and transaction banking services for global trading companies and their clients, per the press release. With its latest funding round, the company aims to expand real-time payments and banking services to more small and medium-sized companies, the release said. Tensec says its clients handle $10 billion in annual trade volume. The company anticipates that its pending expansion into Europe and Asia will increase this annual trading volume to $30 billion, per the press release. 'SMBs drive nearly half of global trade but have long been excluded from the financial tools that larger players rely on,' Helcio Nobre, CEO and co-founder of Tensec, said in a statement. 'We're flipping the model by empowering global trading companies to deliver these services directly to their partners—making global commerce faster, cheaper and more accessible.' Tensec, like other cross-border fintechs, says it's 'targeting the massive cross-border payments infrastructure that still runs on 40-year-old SWIFT technology.' Global cross-border payments 'remain largely untouched by innovation,' Tensec said in the release. Meanwhile, other cross-border payment providers have been attracting investors recently. Last month, Palla Financial, another cross-border payments provider, received $14.5 million from Revolution Ventures, Y Combinator, Meta Fund and other investors. That same week, Conduit Technology, the cross-border payments provider using stablecoins, raised $36 million from Dragonfly and Altos Ventures and other investment firms. Alongside fundraising activities among cross-border payment companies, payment veterans are partnering with their international counterparts. In April, PayPal Holdings subsidiary Xoom teamed up with Tencent to provide cross-border payments for Weixin Pay users. As part of the deal, customers in the U.S., Canada and Europe can access the service, but the company said it planned to expand the offering to more markets. Recommended Reading Payoneer CEO sees trade bumps as short-term Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
